Actinium Pharmaceuticals (AMEX:ATNM) Received B. Riley’s Coverage; Old Point Financial Has 3.86 Sentiment

December 6, 2017 - By Marguerite Chambers

Among 4 analysts covering Actinium Pharmaceuticals (AMEX:ATNM), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Actinium Pharmaceuticals has $12 highest and $3.0 lowest target. $6.50’s average target is 828.57% above currents $0.7 stock price. Actinium Pharmaceuticals had 5 analyst reports since October 15, 2015 according to SRatingsIntel. On Thursday, September 14 the stock rating was initiated by Maxim Group with “Buy”. FBR Capital initiated Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) on Thursday, October 15 with “Outperform” rating. The firm has “Buy” rating by Oppenheimer given on Thursday, November 9. The stock of Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) has “Buy” rating given on Thursday, August 25 by Roth Capital.

Old Point Financial Corporation operates as the bank holding firm for The Old Point National Bank of Phoebus that provides consumer, mortgage, and business banking services for individual, retail, and commercial customers. The company has market cap of $145.74 million. The firm offers deposit products, including interest-bearing transaction accounts, money market deposit accounts, savings accounts, time deposits, and demand deposits. It has a 33.38 P/E ratio. It also provides real estate construction and real estate mortgage loans, such as residential 1-4 family mortgages, commercial real estate loans, second mortgages, and equity lines of credit; and other loans, as well as cash management services.

Since June 15, 2017, it had 3 insider purchases, and 0 selling transactions for $18,370 activity. The insider SETH SANDESH bought $8,725. Another trade for 5,000 shares valued at $5,550 was bought by Berger Mark Stanley. O’Loughlin Steve had bought 3,500 shares worth $4,095 on Thursday, June 15.

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The company has market cap of $56.14 million. The companyÂ’s proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. It currently has negative earnings. The Company’s lead product candidate is Iomab-B that is in Phase III clinical studies in refractory or relapsed acute myeloid leukemia patients over the age of 55 for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant.

Investors sentiment decreased to 1.29 in Q2 2017. Its down 0.28, from 1.57 in 2017Q1. It worsened, as 4 investors sold Actinium Pharmaceuticals, Inc. shares while 3 reduced holdings. 3 funds opened positions while 6 raised stakes. 4.20 million shares or 12.85% more from 3.72 million shares in 2017Q1 were reported. Barclays Plc invested in 15,000 shares. Vanguard Grp holds 0% or 2.14M shares in its portfolio. Raymond James Svcs Inc reported 18,200 shares. Geode Mgmt Lc holds 0% in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) or 191,249 shares. 12,000 are owned by Sns Finance Group Lc. Moreover, Blackrock has 0% invested in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM). Dowling & Yahnke Ltd, California-based fund reported 22,870 shares. State Street holds 11,700 shares. Art Advisors Limited Liability Co holds 0% of its portfolio in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) for 15,105 shares. Creative Planning holds 0% in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) or 3,939 shares. Renaissance Limited Liability Corp has invested 0% in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM). California Public Employees Retirement Sys reported 0% in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM). Hartford Mngmt stated it has 0% in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM). Da Davidson And invested 0% in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM). National Bank Of Montreal Can accumulated 2,500 shares or 0% of the stock.

The stock 0.65% or $0 during the last trading session, reaching $0.7. It is down 15.34% since December 6, 2016 and is downtrending. It has underperformed by 32.04% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By :